CUTISS Secures CHF 56 Million in Series C Funding for Innovative Skin Graft Technology

CUTISS, a pioneering company in the field of tissue therapeutics and regenerative medicine, has successfully closed a Series C funding round valued at CHF 56 million. This funding, announced on September 10, 2025, brings the total investment raised by CUTISS to over CHF 125 million. The significant capital will be utilized for a variety of initiatives aimed at transforming the skin surgery landscape.

Advancing Clinical Trials

The primary focus of this funding is to support the ongoing Phase 3 clinical trials of CUTISS’s lead product, denovoSkin™, a personalized bio-engineered skin graft. DenovoSkin™ aims to provide a revolutionary alternative to traditional skin grafting techniques, greatly improving patient outcomes. The product is currently undergoing trials across Europe, where early results have been promising.

Dr. Daniela Marino, CEO and co-founder of CUTISS, expressed her gratitude toward both current and new investors, emphasizing that their trust reinforces CUTISS’s vision to deliver groundbreaking skin therapies. Dr. Marino stated, “The successful closing demonstrates confidence in our vision and ability to bring transformative skin therapies to patients.”

With funding secured, the next steps for CUTISS will include the finalization of the ongoing trials and preparing for the commercialization of denovoSkin™, making it readily accessible to medical professionals and patients who need it.

Future Production Plans

In a strategic move to bolster its production capabilities, CUTISS has forged a collaboration agreement with the Rode Kruis Ziekenhuis, a prominent clinical trials center in the EU. This agreement paves the way for what could become CUTISS's first international commercial production facility in the Netherlands, contingent upon the approval of denovoSkin™. This production center aims to utilize cutting-edge technology to manufacture personalized tissue therapies on a larger scale, further supporting the company’s mission to innovate in skin care.

Nadine Vieleers, CEO of Rode Kruis Ziekenhuis, remarked on their dedication to advancing burn care and expressed excitement about the collaboration: “As a clinical institution dedicated to advancing burn care, we're committed to supporting CUTISS and the development of denovoSkin™.”

Transforming Skin Surgery

The denovoSkin™ graft presents a transformative solution for patients suffering from skin loss due to burns, surgical procedures, or chronic wounds. Traditional skin grafts often come with complications and limitations, whereas denovoSkin™ is designed to offer a more personalized approach based on individual patient needs.

CUTISS’s automated manufacturing platform, designed for personalized tissue therapy, represents a significant advancement in the field. By ensuring scalability and efficiency, the company is poised to meet market demands once the product is approved.

In conclusion, the successful closing of this funding round not only signifies a pivotal moment for CUTISS but also highlights the increasing interest in regenerative medicine and innovative therapies. As CUTISS navigates through its clinical trials and prepares for market entry, the potential impact on skin surgery could be monumental, benefitting countless patients across the globe. The horizon looks bright for CUTISS as it continues to push the boundaries of what's possible in tissue therapeutic solutions.